专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012047775A1 PHARMACEUTICAL COMBINATIONS 审中-公开
标题翻译：药物组合
公开(公告)号：WO2012047775A1
公开(公告)日：2012-04-12
申请号：PCT/US2011/054536
申请日：2011-10-03
申请人： NOVARTIS AG , CHEN, Yan , HUANG, Xizhong , MURPHY, Leon , NYFELER, Beat
发明人： CHEN, Yan , HUANG, Xizhong , MURPHY, Leon , NYFELER, Beat
IPC分类号： A61K31/4188 , A61K31/4745 , A61P35/00
CPC分类号： A61K31/436 , A61K31/4188 , A61K31/4745 , A61K31/496 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol- 3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
摘要翻译：本发明涉及药物组合，其包含（a）mTOR催化抑制剂，例如催化磷脂酰肌醇-3-激酶（PI3K）和作为咪唑并喹啉衍生物的mTOR抑制剂化合物和（b）至少一种变构mTOR抑制剂化合物和任选的至少一种用于同时，分别或顺序使用的药学上可接受的载体，特别是用于治疗雷帕霉素（mTOR）激酶依赖性增殖性疾病的哺乳动物靶标; 以及这种组合在治疗mTOR激酶依赖性增殖性疾病中的应用; 包含这种组合的药物组合物; 使用这种组合来制备用于治疗增殖性疾病的药物; 商业包装或产品，其包含作为同时，分开或顺序使用的组合制剂的组合; 以及治疗温血动物，特别是人的方法。

2. 发明申请

WO2015022609A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：治疗癌症的联合治疗
公开(公告)号：WO2015022609A1
公开(公告)日：2015-02-19
申请号：PCT/IB2014/063782
申请日：2014-08-07
申请人： NOVARTIS AG , CHEN, Yan , HUANG, Xizhong , KIM, Sunkyu
发明人： CHEN, Yan , HUANG, Xizhong , KIM, Sunkyu
IPC分类号： A61K31/519 , A61K31/551 , A61P35/00
CPC分类号： A61K31/519 , A61K31/138 , A61K31/4196 , A61K31/436 , A61K31/4439 , A61K31/5377 , A61K31/551 , A61K31/5513 , A61K31/565 , A61K31/5685 , A61K45/06 , A61K2300/00
摘要： The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
摘要翻译：本公开涉及药物组合，其包含（1）作为CDK抑制剂或其药学上可接受的盐的第一药剂和（2）作为抗激素剂或其药学上可接受的盐的第二药剂。本公开还涉及药物组合，其包含（1）第一药剂，其为CDK抑制剂或其药学上可接受的盐，（2）第二药剂，其为抗激素剂或其药学上可接受的盐，和（ 3）作为调节PI3K / Akt / mTOR途径的药剂的第三药剂或其药学上可接受的盐。

3. 发明申请

WO2013006532A1 COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER 审中-公开
标题翻译：包含CDK4 / 6抑制剂和用于治疗癌症的PI3K抑制剂的组合治疗
公开(公告)号：WO2013006532A1
公开(公告)日：2013-01-10
申请号：PCT/US2012/045199
申请日：2012-07-02
申请人： NOVARTIS AG , KIM, Sunkyu , DOSHI, Shivang , HAAS, Kristy , KOVATS, Steven , HUANG, Alan Xizhong , CHEN, Yan
发明人： KIM, Sunkyu , DOSHI, Shivang , HAAS, Kristy , KOVATS, Steven , HUANG, Alan Xizhong , CHEN, Yan
IPC分类号： A61K31/4439 , A61K31/519 , A61K31/535 , A61P35/00
CPC分类号： A61K31/519 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.
摘要翻译： CDK4 / 6抑制剂与用于治疗癌症的P3Kinase抑制剂的组合。

4. 发明公开

EP2624831A1 PHARMACEUTICAL COMBINATIONS 审中-公开
标题翻译：药物组合
公开(公告)号：EP2624831A1
公开(公告)日：2013-08-14
申请号：EP11770611.9
申请日：2011-10-03
申请人： Novartis AG
发明人： CHEN, Yan , HUANG, Xizhong , MURPHY, Leon , NYFELER, Beat
IPC分类号： A61K31/4188 , A61K31/4745 , A61P35/00
CPC分类号： A61K31/436 , A61K31/4188 , A61K31/4745 , A61K31/496 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol- 3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.

5. 发明公开

EP3033086A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER 有权
标题翻译：联合疗法治疗癌症
公开(公告)号：EP3033086A1
公开(公告)日：2016-06-22
申请号：EP14752433.4
申请日：2014-08-07
申请人： Novartis AG
发明人： CHEN, Yan , HUANG, Xizhong , KIM, Sunkyu
IPC分类号： A61K31/519 , A61K31/551 , A61P35/00
CPC分类号： A61K31/519 , A61K31/138 , A61K31/4196 , A61K31/436 , A61K31/4439 , A61K31/5377 , A61K31/551 , A61K31/5513 , A61K31/565 , A61K31/5685 , A61K45/06 , A61K2300/00
摘要： The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

6. 发明公开

EP2726074A1 COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER 有权
标题翻译：具有使用在癌症治疗中的CDK4 / 6抑制剂和PI3K的抑制剂联合治疗
公开(公告)号：EP2726074A1
公开(公告)日：2014-05-07
申请号：EP12735408.2
申请日：2012-07-02
申请人： Novartis AG
发明人： KIM, Sunkyu , DOSHI, Shivang , HAAS, Kristy , KOVATS, Steven , HUANG, Alan Xizhong , CHEN, Yan
IPC分类号： A61K31/4439 , A61K31/519 , A61K31/535 , A61P35/00
CPC分类号： A61K31/519 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.
摘要翻译：一个CDK4 / 6抑制剂的组合以及用于治疗癌症的P3Kinase抑制剂。

7. 发明授权

EP2726074B1 COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER 有权
标题翻译：包含CDK4 / 6抑制剂和PI3K抑制剂的组合治疗用于治疗癌症
公开(公告)号：EP2726074B1
公开(公告)日：2018-04-04
申请号：EP12735408.2
申请日：2012-07-02
申请人： Novartis AG
发明人： KIM, Sunkyu , DOSHI, Shivang , HAAS, Kristy , KOVATS, Steven , HUANG, Alan Xizhong , CHEN, Yan
IPC分类号： A61K31/4439 , A61K31/519 , A61K31/5377 , A61K45/06 , A61P35/00
CPC分类号： A61K31/519 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式